BHST Stock Chart & Stats
589.80
0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range600.00 - 600.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)57.00
Market Cap
₪110.70M
Enterprise Value66.16
Total Cash (Recent Filing)₪16.22M
Total Debt (Recent Filing)₪17.55M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 30, 2026EPS Estimate
-41.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding22,667,843
10 Day Avg. Volume57
30 Day Avg. Volume57
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.75
Price to Sales (P/S)2.77
P/FCF Ratio-9.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₪2,713.14Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginRapid revenue expansion alongside a gross margin near 59% indicates improving underlying economics and growing commercial adoption. If maintained, this gross-profit base can support investment in the platform, broaden operating leverage, and strengthen the company’s ability to scale its nutraceutical and ingredient businesses.
CDMO Commercial TractionThe first major CDMO manufacturing agreement provides external validation that BioHarvest’s botanical synthesis platform can address premium ingredient applications. A committed production program and potential multi-year revenue could diversify the business beyond VINIA and create a foundation for recurring manufacturing growth.
Improved Cash PositionThe substantial year-over-year increase in cash and deposits gives BioHarvest greater near-term capacity to fund operations, technology development, and CDMO preparation. Management’s emphasis on preserving cash and avoiding equity raises may also reduce immediate financing pressure while the company pursues scale.
Bears Say
Persistent UnprofitabilityDespite strong revenue and gross margins, BioHarvest has not yet converted its business model into operating profitability. Continued net, operating, and EBITDA losses indicate that expenses remain too high relative to gross profit, limiting internally funded growth and leaving execution dependent on eventual scale benefits.
Ongoing Cash Burn And Rising DebtNegative operating and free cash flow show that the company continues to consume capital to run and expand the business. Combined with higher debt, this reduces financial flexibility and could constrain investment choices or increase reliance on financing before sustained cash generation is achieved.
Lowered 2026 OutlookThe guidance reduction signals weaker near-term revenue conversion and a slower path to profitability than previously expected. The lower VINIA outlook and wider consolidated EBITDA loss suggest the strategic shift toward CDMO capacity is imposing measurable financial costs before its anticipated benefits begin contributing.
BioHarvest Sciences News
BHST FAQ
What was BioHarvest Sciences’s price range in the past 12 months?
BioHarvest Sciences lowest stock price was 600.00 and its highest was 600.00 in the past 12 months.
What is BioHarvest Sciences’s market cap?
BioHarvest Sciences’s market cap is ₪110.70M.
When is BioHarvest Sciences’s upcoming earnings report date?
BioHarvest Sciences’s upcoming earnings report date is Nov 30, 2026 which is in 68 days.
How were BioHarvest Sciences’s earnings last quarter?
BioHarvest Sciences released its earnings results on Aug 11, 2026. The company reported -51.248 earnings per share for the quarter, missing the consensus estimate of -35.572 by -15.676.
Is BioHarvest Sciences overvalued?
According to Wall Street analysts BioHarvest Sciences’s price is currently Undervalued.
Does BioHarvest Sciences pay dividends?
BioHarvest Sciences does not currently pay dividends.
What is BioHarvest Sciences’s EPS estimate?
BioHarvest Sciences’s EPS estimate is -41.6.
How many shares outstanding does BioHarvest Sciences have?
BioHarvest Sciences has 22,667,843 shares outstanding.
What happened to BioHarvest Sciences’s price movement after its last earnings report?
BioHarvest Sciences reported an EPS of -51.248 in its last earnings report, missing expectations of -35.572. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of BioHarvest Sciences?
Currently, no hedge funds are holding shares in IL:BHST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioHarvest Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
₪2,713.14 (― Downside)
₪2,713.14 (― Downside)
Blogger Sentiment
Bullish
IL:BHST Sentiment 67%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
BHST Earnings Call
Q2 2026
0:00 / 0:00
BHST Stock 12 Month Forecast
Average Price Target
$2,713.14